A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, with or without chemotherapy in subjects with advanced pancreatic cancer.

Authors: Bruno Bockorny, Julia Berg, Andrea J. Bullock, Peter D. Whooley, Mary Linton Bounetheau Peters, Nora K. Horick, Monika Vyas, Taru E. Muranen, Manuel Hidalgo

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4231

Source: Full article

---

Abstract

TPS4231